http://seekingalpha.com/article/2575735-neurotrope-tackles-alzheimers-disease-with-novel-mechanism
Summary
Neurotrope, Inc. is developing therapeutics for neurodegenerative diseases such as Alzheimer’s Disease (AD).
The company’s lead compound, bryostatin-1, is a natural compound isolated from a tiny, ocean dwelling organism.
Bryostatin-1 activates protein kinase C (PKC) and represents a novel treatment option for AD that is supported by extensive preclinical data.
The company is also developing an AD diagnostic test with early results showing sensitivity (correctly diagnosing AD) ≥ 97% and specificity (correctly identifying individuals without AD) ≥ 96%.
Neurotrope has a basic market capitalization of only $14 million, with $10+ million in cash in the bank and data from a Phase 2a study coming in early 2015.
Neurotrope, Inc (OTCQB:NTRP) is seeking to commercialize technology developed at and exclusively licensed from the Blanchette Rockefeller Neurosciences Institute (BRNI) for therapeutic and diagnostic applications in Alzheimer’s Disease (AD) and other neurodegenerative disorders. We believe the company has a promising technology, is highly undervalued, and well-funded to show initial proof-of-concept for its lead development candidate in early 2015.
…Alzheimer’s Disease…